Send to

Choose Destination
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. doi: 10.1093/nar/gkx1121.

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Author information

Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK.
Department of Structural & Molecular Biology, University College London, London WC1E 6BT, UK.
School of Mathematical and Computer Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK.
School of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK.
MRC Centre for inflammation Research, University of Edinburgh, Edinburgh EH16 4TJ, UK.
Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK.
Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge CB2?0QQ, UK.
Department of Microbiology, Monash University, Clayton 3800, Australia.
PIQUR Therapeutics, Basel 4057, Switzerland.
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
Spedding Research Solutions SAS, Le Vésinet 78110, France.


The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, and its precursor IUPHAR-DB, have captured expert-curated interactions between targets and ligands from selected papers in pharmacology and drug discovery since 2003. This resource continues to be developed in conjunction with the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS). As previously described, our unique model of content selection and quality control is based on 96 target-class subcommittees comprising 512 scientists collaborating with in-house curators. This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015. Our relationship matrix now describes ∼9000 ligands, ∼15 000 binding constants, ∼6000 papers and ∼1700 human proteins. As an important addition, we also introduce our newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, This has been 'forked' from the well-established GtoPdb data model and expanded into new types of data related to the immune system and inflammatory processes. This includes new ligands, targets, pathways, cell types and diseases for which we are recruiting new IUPHAR expert committees. Designed as an immunopharmacological gateway, it also has an emphasis on potential therapeutic interventions.

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center